-
1 . Periodical
KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML
- 저자
- by Arnan, Monteserrat; Patel, Anand Ashwin; Esteve, Jordi; Morris, Lawrence; Schiller, Gary J., et al.
- 소스
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p5973-5973, 1p